View:
United States securities and exchange commission logo
August 18, 2022
Henry Ji
Chairman of the Board, CEO and President
Sorrento Therapeutics, Inc.
4955 Directors Place
San Diego, CA 92121
Re: Sorrento
Therapeutics, Inc.
Form 10-K for the
year ended December 31, 2021
Filed March 11,
2022
Form 10-Q for the
period ended March 31, 2022
Filed May 5, 2022
Form 10-Q for the
period ended June 30, 2022
Filed August 15,
2022
File No. 001-36150
Dear Dr. Ji:
We have limited our review of your filings to the financial
statements and related
disclosures and have the following comment. In our comment, we may ask
you to provide us
with information so we may better understand your disclosure.
Please respond to the comment within ten business days by
providing the requested
information or advise us as soon as possible when you will respond. If
you do not believe our
comment applies to your facts and circumstances, please tell us why in
your response.
After reviewing your
response to the comment, we may have additional comments.
Form 10-Q for the period ended June 30, 2022
Notes to Unaudited Consolidated Financial Statements
7. Debt, page 15
1. Please provide us with
your accounting basis, citing relevant authoritative literature, to
account for the Consent
Under and Amendment No. 4 to your Indenture agreement as a
troubled debt
restructuring rather than a modification or extinguishment.
In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.
Henry Ji
Sorrento Therapeutics, Inc.
August 18, 2022
Page 2
You may contact Sasha Parikh at 202-551-3627 or Daniel Gordon at
202-551-3486 with
any questions.
FirstName LastNameHenry Ji Sincerely,
Comapany NameSorrento Therapeutics, Inc.
Division of Corporation
Finance
August 18, 2022 Page 2 Office of Life Sciences
FirstName LastName